Biotechnology firm Regeneron Pharmaceuticals says it would acquire 23andMe's personal genome service, total health, and research services business lines, and its biobank of customers' genetic samples. Regeneron said San Francisco-headquartered 23andMe would continue to offer all consumer genome services.

In your assessment, what factors caused 23andMe to lose its stellar valuation?

May 2025

https://www.businessinsider.com/23andme-bought-regeneron-chapter-11-bankruptcy-assets-anne-wojcicki-2025-5

by Choobeen

4 comments

  1. The $6B valuation came from two things; hype and free money (low interest rates). After the 2023 data breach the trust was lost and the hype was gone.

  2. The thought of a company being able to buy a “Biobank of customers’ genetic samples” for $256mm should be incredibly unsettling for anyone who’s completed one of 23andMe’s tests…

  3. The investment thesis is that this data would be massively valuable to pharmaceutical companies. It wasn’t

  4. lol people willingly giving dna samples is beyond me.

Comments are closed.